A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR. (Q38899715)

7 September 2017

title

A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR. (English)

1 reference

7 September 2017

1 reference

Jing Zeng

1

1 reference

7 September 2017

Ran Liu

series ordinal

2

1 reference

7 September 2017

Jinjing Wang

series ordinal

3

1 reference

7 September 2017

Yi Fang

series ordinal

4

1 reference

7 September 2017

publication date

14 March 2015

1 reference

Journal of Cancer Research and Clinical Oncology

7 September 2017

published in

1 reference

7 September 2017

volume

141

1 reference

7 September 2017

issue

11

1 reference

7 September 2017

page(s)

1899-1907

1 reference

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

HLA-DR human histocompatibility leukocyte antigens-restricted lymphocyte-monocyte interactions in the release from monocytes of acidic isoferritins that suppress hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

HLA class II antibodies in the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Humanization and characterization of the anti-HLA-DR antibody 1D10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

MHC class II isotype-specific signaling complex on human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Bispecific antibodies for cancer immunotherapy: Current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Antibody therapeutics in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Hybrid antibodies can target sites for attack by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Immunotherapeutic perspective for bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Monoclonal antibodies for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

Traditional treatment approaches in B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1949-7

A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells

21 January 2018

1 reference

12 December 2020

Monoclonal antibody therapy of cancer

1 reference

12 December 2020

A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

1 reference

12 December 2020

Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma

1 reference

12 December 2020

Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma

1 reference

12 December 2020

CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines

1 reference

12 December 2020

Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression

1 reference

12 December 2020

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia

1 reference

12 December 2020

1 reference

12 December 2020

Biochemical characteristics and partial amino acid sequence of the receptor-like human B cell and carcinoma antigen CDw40.

1 reference

12 December 2020

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

1 reference

12 December 2020

A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes

1 reference

12 December 2020

Design and generation of DVD-Ig™ molecules for dual-specific targeting

1 reference

12 December 2020

Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.

1 reference

12 December 2020

A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.

1 reference

12 December 2020

Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation.

1 reference

12 December 2020

10.1007/S00432-015-1949-7

Identifiers

DOI

1 reference

release_l6kfor2fejgnvcwggxmlalufla

7 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l6kfor2fejgnvcwggxmlalufla

24 November 2022

mapped directly with Wikidata item

1 reference